<DOC>
	<DOCNO>NCT01168167</DOCNO>
	<brief_summary>Recent clinical trial combination antiretroviral therapy ( cART ) contain first approve integrase inhibitor ( i.e . raltegravir ) demonstrate rapid decay HIV-1 RNA plasma , compare conventional potent antiretroviral combination . This observe especially early phase ( week 12 ) follow initiation cART . To explain , two mechanistic hypothesis develop : 1 . - Macrophage reservoir death hypothesis . A major source virus production second phase decay believe long-lived infected cell continuous virus production - e.g . macrophage . An accumulation unintegrated , episomal HIV-1 cDNAs promote apoptosis ( Li et al . Embo J . 2001 ; 20 : 3272 ) . In case HIV superinfection productively infect cell , INI-based cART may induce apoptosis thus contribute decrease HIV RNA load second phase decay . However , study thus far addressed consequence INI treatment HIV-1 cDNA specie cell population vivo . 2 . - Resting CD4 T-cell reservoir integration block hypothesis . Resting CD4 T-cells may represent substantial reservoir HIV replication second phase decay well . A special characteristic cell HIV-1 cDNA typically localized nucleus not-integrated form ( Chun et al. , PNAS 1997 ; 94:13193 ) . These rest cell likely integrate HIV-DNA upon activation contribute HIV viremia viral spread . Conceptually , integration could prevent RGV , RTI PI . An accumulation circular episomal HIV-1 cDNA specie may also consequence RGV treatment cell type . Patient disposition : To explore raltegravir-induced shift HIV-1 cDNA specie vivo , non-interventional clinical observation investigates dynamic three major HIV-1 cDNA specie ( total HIV-1 cDNA , HIV-1 integrants host cell genome , episomal HIV-1 2-LTR circle ) period 4 month two group patient start cART single study center . Patients begin cART regular clinical routine 2N ( ) RTI plus either ( n=10 patient ) raltegravir ( n=10 patient ) boost protease inhibitor/ alternatively NNRTI offer participate observation . Only patient offer participate trial antiretroviral drug mention concomitant drug relevant impact antiretroviral 's pharmacokinetics administer . At time study inclusion , patient characterise HIV-1 RNA load &gt; 5,000 copies/mL CD4-cell count &gt; 200/µL within 12 week cART initiation . Preliminary analysis PBMCs HIV-infected patient indicate three major HIV-1 cDNA specie quantify real-time PCR baseline condition .</brief_summary>
	<brief_title>Impact Raltegravir HIV-1 cDNA Slope Following Antiretroviral Therapy ( ART ) Initiation</brief_title>
	<detailed_description />
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Initiation antiretroviral therapy , consist 2 nucleoside/ nucleotide reverse transcriptase inhibitor physician 's disposition plus third substance , i.e . either raltegravir ( n=10 patient ) standard third substance ( efavirenz boost protease inhibitor ) Men woman document HIV1 infection , treat study center age least 18 year old physical examination vital sign , accord treat physician give hint active AIDSdefining illness serious disease patient naive cART therapy interruption least 3 month last available HIV1 RNA &gt; 5,000 copies/mL within 3 month prior cART initiation last available CD4cell count show least 200 cells/µL within 3 month prior cART initiation accord GermanAustrian antiretroviral treatment recommendation , give therapy indication cART mention drug administration concomitant drug relevant impact antiretroviral 's pharmacokinetics document problem patient visit medicationadherence condition disease require medication may interact relevantly cART</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Antiretroviral Therapy , Highly Active</keyword>
	<keyword>MK 0518</keyword>
	<keyword>HIV-1 DNA specie</keyword>
	<keyword>viral slope</keyword>
	<keyword>Ribonucleic Acid</keyword>
	<keyword>DNA , Complementary</keyword>
</DOC>